Repatha vs Lisinopril Side-Effect Profile: Head-to-Head Comparison

What Are These Two Drugs Actually Doing?

Evolocumab and lisinopril both reduce cardiovascular risk, but they do so at entirely different points in the disease cascade. Evolocumab blocks PCSK9, a protein that degrades LDL receptors on liver cells. Lisinopril inhibits angiotensin-converting enzyme, reducing angiotensin II production and lowering systemic vascular resistance. The two drugs are not competing for the same clinical slot.

Evolocumab (Repatha): Mechanism and Approved Uses

Evolocumab is a fully human monoclonal IgG2 antibody that binds PCSK9 and prevents it from destroying hepatic LDL receptors [1]. With more receptors available, the liver clears more LDL-C from circulation. The FDA approved evolocumab in 2015 for adults with primary hyperlipidemia and for homozygous familial hypercholesterolemia [2].

In FOURIER (N=27,564), patients already on moderate-to-high-intensity statin therapy achieved a mean LDL-C reduction of 59% from a median baseline of 92 mg/dL, reaching a median on-treatment LDL-C of 30 mg/dL [1]. The primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) fell by 15% relative risk reduction over a median 2.2 years of follow-up (HR 0.85; 95% CI 0.79 to 0.92; P<0.001) [1].

Lisinopril (Zestril, Prinivil): Mechanism and Approved Uses

Lisinopril works by inhibiting ACE, the enzyme that converts angiotensin I to angiotensin II [3]. Lower angiotensin II means less vasoconstriction, less aldosterone release, and lower blood pressure. The FDA has approved lisinopril for hypertension, heart failure as an adjunct to diuretics and digitalis, and for stable post-MI patients to improve survival [4].

ALLHAT (N=33,357) compared lisinopril against chlorthalidone and amlodipine in high-risk hypertensive patients [5]. Lisinopril produced equivalent rates of fatal coronary heart disease and nonfatal MI compared to chlorthalidone, but showed significantly higher rates of stroke (RR 1.15; 95% CI 1.02 to 1.30) and combined cardiovascular disease events [5]. Those differences were more pronounced in Black patients, likely reflecting blunted antihypertensive response to ACE inhibition in that population.

Side-Effect Profiles Compared

The side-effect profiles of these two drugs share almost no overlap. Evolocumab's adverse events are largely injection-site and musculoskeletal; lisinopril's are largely related to bradykinin accumulation and renin-angiotensin blockade.

Evolocumab Side Effects

Injection-site reactions were the most common adverse event in FOURIER, occurring in 6.3% of evolocumab patients versus 5.7% of placebo patients [1]. Most reactions were mild (erythema, bruising, pain) and resolved without intervention.

Myalgia appeared in 5.1% of evolocumab-treated patients in FOURIER [1]. This is clinically relevant because many patients on PCSK9 inhibitors are also on statins, which independently cause muscle symptoms. Disentangling statin-related myalgia from evolocumab-related myalgia requires careful history and, if needed, temporary statin dose reduction.

Neurocognitive effects were a pre-approval concern. A dedicated sub-study, EBBINGHAUS (N=1,974), embedded within FOURIER found no significant difference in cognitive function between evolocumab and placebo groups over 19 months of follow-up [6]. Scores on the Cambridge Neuropsychological Test Automated Battery were equivalent.

Diabetes risk does not appear elevated with PCSK9 inhibitors, unlike statins, which increase new-onset diabetes risk by approximately 10% [7]. FOURIER data showed no signal for new-onset diabetes with evolocumab [1].

Serious adverse events occurred in 24.8% of evolocumab patients and 26.7% of placebo patients in FOURIER, meaning the drug did not add net harm in that domain [1].

Lisinopril Side Effects

Dry cough is the most common reason patients discontinue lisinopril. ACE inhibitors block the degradation of bradykinin; accumulated bradykinin stimulates sensory C-fibers in the bronchial mucosa. Incidence ranges from 10% to 15% in clinical practice, with higher rates reported in Asian populations (up to 35 to 44%) [8]. ALLHAT did not systematically track cough discontinuation, but withdrawal from assigned treatment for any reason was higher in the lisinopril arm [5].

Angioedema is rare but potentially life-threatening. ACE inhibitor-induced angioedema occurs in approximately 0.1 to 0.7% of patients, with Black patients at 4- to 5-fold higher risk [9]. The mechanism again involves bradykinin accumulation causing deep dermal and submucosal edema, most frequently in the face, lips, tongue, and larynx [9]. Any patient presenting with facial swelling on lisinopril needs emergency evaluation.

Hyperkalemia results from reduced aldosterone secretion. Clinically significant hyperkalemia (potassium >5.5 mEq/L) occurs in roughly 1 to 10% of patients, with risk sharply elevated in patients with chronic kidney disease, those taking potassium-sparing diuretics, or those using NSAIDs [10].

Hypotension, especially first-dose hypotension, is a real risk in volume-depleted patients or those on diuretics. The 2021 ACC/AHA Guideline on Heart Failure recommends starting lisinopril at 2.5 to 5 mg daily and titrating up slowly to mitigate this [11].

Renal function changes are expected early in therapy. A modest rise in serum creatinine (up to 30% above baseline) is acceptable and generally indicates the drug is working as intended by reducing glomerular hyperfiltration [10]. Rises beyond that threshold warrant re-evaluation.

Who Gets Which Drug?

These are not competitive options for the same indication. A clinician choosing between them is almost certainly dealing with a patient who has multiple comorbidities requiring both drugs.

When Evolocumab Is the Right Choice

Evolocumab fits patients with established atherosclerotic cardiovascular disease (ASCVD) who cannot achieve adequate LDL-C reduction on maximally tolerated statin therapy alone [12]. The 2022 ACC Expert Consensus Decision Pathway recommends PCSK9 inhibitor therapy when LDL-C remains at or above 70 mg/dL despite high-intensity statin plus ezetimibe in patients with very high cardiovascular risk [12].

Patients with statin intolerance represent another clear indication. The GAUSS-3 trial (N=511) tested evolocumab head-to-head against ezetimibe in statin-intolerant patients and found a 52.8% greater reduction in LDL-C with evolocumab (P<0.001) [13].

Homozygous familial hypercholesterolemia is an approved indication at the higher 420 mg monthly dose [2].

When Lisinopril Is the Right Choice

Lisinopril is a first-line antihypertensive for patients with diabetes, chronic kidney disease (CKD) with proteinuria, or post-MI left ventricular dysfunction [11]. The 2017 ACC/AHA High Blood Pressure Guideline lists ACE inhibitors as preferred therapy in patients with CKD and albuminuria because of their proven renoprotective effect beyond blood pressure reduction [14].

In heart failure with reduced ejection fraction (HFrEF), ACE inhibitors have a mortality benefit established across multiple large trials. CONSENSUS (N=253) showed enalapril reduced mortality by 40% at 6 months in severe HF; subsequent data with lisinopril mirrored this class effect [15].

Patients Who May Need Both

A 65-year-old with post-MI ASCVD, LDL-C of 85 mg/dL on atorvastatin 40 mg, and hypertension with early CKD might appropriately be on lisinopril for blood pressure and renal protection while also receiving evolocumab for residual LDL-C burden. These drugs do not interact pharmacokinetically. Evolocumab is metabolized via proteolytic degradation typical of large proteins, not via hepatic CYP enzymes, so no dose adjustments are needed when combining with lisinopril [2].

Cost, Access, and Adherence Considerations

Price is a real barrier. Evolocumab carries a list price near $6,000 per year, though manufacturer copay cards and patient assistance programs frequently reduce out-of-pocket costs for insured patients. Lisinopril is generic and available for under $10 per month at most pharmacies [16].

Insurance Coverage for Evolocumab

Most major payers require prior authorization for PCSK9 inhibitors. Typical requirements include documentation of LDL-C at or above 70 mg/dL (or 100 mg/dL in primary prevention) despite maximally tolerated statin plus ezetimibe, or a confirmed diagnosis of familial hypercholesterolemia [12]. The 2021 ICER report found evolocumab cost-effective at prices below approximately $4,500, $5,500 per year, which aligns with negotiated net prices after rebates [17].

Adherence Patterns

Lisinopril's once-daily oral dosing is generally well-tolerated in adherent patients, but the cough side effect drives significant discontinuation. One retrospective cohort study found 12-month ACE inhibitor persistence rates as low as 45 to 50% in real-world hypertensive populations [18]. Patients who switch from ACE inhibitors to ARBs (angiotensin receptor blockers) because of cough typically maintain blood pressure control with similar efficacy.

Evolocumab's biweekly injection schedule has adherence challenges of its own. FOURIER used a run-in period to select adherent patients, so real-world persistence may be lower than trial data suggest. Self-injection training and auto-injector devices have improved usability since approval.

Safety in Special Populations

Kidney Disease

Lisinopril requires dose adjustment in CKD. The prescribing information recommends starting at 2.5 to 5 mg daily for patients with creatinine clearance below 30 mL/min [4]. Hyperkalemia risk rises substantially in advanced CKD, and lisinopril is generally avoided in patients with creatinine clearance below 10 mL/min or on hemodialysis [10].

Evolocumab does not require dose adjustment in renal impairment. Pharmacokinetic data from the evolocumab prescribing information show no clinically meaningful difference in exposure between patients with mild-to-severe renal impairment and those with normal kidney function [2].

Pregnancy

Both drugs are contraindicated in pregnancy. Lisinopril causes fetal renal dysgenesis and can produce oligohydramnios, fetal limb contractures, craniofacial deformities, and neonatal death if taken during the second or third trimester [4]. The FDA classifies ACE inhibitors as Category D (now incorporated into the 2015 Pregnancy and Lactation Labeling Rule framework) for the second and third trimesters [4].

Evolocumab's safety in pregnancy has not been established. Animal studies with murine surrogates suggest potential effects on fetal development; women of childbearing potential should use contraception during treatment [2].

Older Adults

Lisinopril in older adults carries heightened risk of first-dose hypotension, particularly in patients on diuretics or with reduced baseline blood pressure. The 2023 American Geriatrics Society Beers Criteria does not list ACE inhibitors as inappropriate in older adults but emphasizes careful monitoring of renal function and electrolytes [19].

Evolocumab has been studied in patients up to 80 years of age in FOURIER with no evidence that older patients experience different rates of serious adverse events [1].

Monitoring Parameters

Patients on lisinopril need periodic checks of serum potassium, serum creatinine, and blood pressure. The 2017 ACC/AHA guideline recommends renal function and electrolyte monitoring within 2 to 4 weeks of initiation or dose increase, then every 3 to 6 months once stable [14].

Evolocumab requires less laboratory surveillance. Fasting lipid panels at 4 to 12 weeks after initiation confirm LDL-C response [12]. Liver function tests and CK are not routinely required unless the patient develops symptoms. No renal monitoring is needed.

What the Evidence Does Not Show

No randomized controlled trial has directly compared evolocumab with lisinopril as competing therapies. FOURIER enrolled patients already on statin therapy with established ASCVD; it did not include a lisinopril comparator arm [1]. ALLHAT compared antihypertensive agents in a high-risk hypertensive population and did not include a lipid-lowering arm [5]. Drawing direct efficacy comparisons between the two drugs is not supported by existing trial data, and any claim that one drug is "better" than the other ignores the fundamental difference in indications.

The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease notes clearly that lipid-lowering therapy and blood pressure-lowering therapy target different risk factors and are frequently co-administered rather than selected as alternatives [20].